Clinical Use of CCR5 Inhibitors in HIV Treatment
Author Information
Author(s): Gilliam Bruce L, Riedel David J, Redfield Robert R
Primary Institution: Institute of Human Virology, University of Maryland School of Medicine
Hypothesis
What is the efficacy and safety of CCR5 antagonists, particularly maraviroc, in treating HIV and other diseases?
Conclusion
CCR5 antagonists, especially maraviroc, show significant potential in treating HIV and may be useful in other clinical situations, but their optimal use is not yet well-defined.
Supporting Evidence
- Maraviroc has been shown to significantly reduce viral load in treatment-experienced patients.
- Patients receiving maraviroc had higher CD4 cell count increases compared to those on placebo.
- CCR5 antagonists may have potential uses in organ transplantation and prevention of HIV transmission.
Takeaway
This study looks at a medicine called maraviroc that helps people with HIV by blocking a part of the virus from entering their cells. It shows promise for treating HIV and possibly other diseases.
Methodology
The study reviewed clinical trials and data on CCR5 antagonists, focusing on maraviroc's efficacy, safety, and resistance profiles.
Potential Biases
Potential bias in reporting due to the focus on a single approved drug and its clinical trials.
Limitations
The study primarily focuses on maraviroc, limiting the generalizability of findings to other CCR5 antagonists.
Participant Demographics
The study included treatment-experienced and treatment-naïve HIV-infected patients from various regions including the U.S., Canada, Australia, and Europe.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website